Project 3: Combination Inhibition of ERK for Pancreatic Cancer Treatment

Andrea Wang-Gillam, MD, PhD, and Channing Der, PhD

Pdac Image 13 Website
PDAC stained for tumor cells (green) and stromal cells (red)

Investigators in Project 3 will examine screening combinations of drugs that may inhibit molecular pathways that support tumor survival in pancreatic cancer. A specific gene is found mutated in 95% of pancreatic ductal adenocarcinomas (PDACs), the deadliest form of pancreatic cancer. Our research and investigators hope to identify combination drug therapies that will overcome these gene mutations and, thus, help treat PDAC patients. Clinical trials based on this research will then begin in PDAC patients.

Research overview for investigators